Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Discontinued Operations - Discontinued Operations (Details)

v3.7.0.1
Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Accounts and other receivables     $ 1,598,994
Inventory, net     1,374,618
Prepaid expenses     170,635
Assets associated with discontinued operations, current     3,144,247
Property and equipment, net of accumulated depreciation     70,973
Patents and trademarks, net of accumulated amortization     34,282
Assets associated with discontinued operations, noncurrent     105,255
Total assets associated with discontinued operations     3,249,502
Accounts payable 21,255   21,255   1,957,938
Accrued liabilities 33,804   33,804   607,659
Deferred revenue     2,300,000
Liabilities associated with discontinued operations, current 55,059   55,059   $ 4,865,597
Lymphoseek sales revenue 9,663 $ 4,227,320 2,926,876 $ 8,001,200  
Grant and other revenue 190  
Total revenue 9,663 4,227,320 2,926,876 8,001,390  
Cost of goods sold 24,216 559,933 388,408 1,093,373  
Gross profit (14,553) 3,667,387 2,538,468 6,908,017  
Research and development 75,196 506,370 358,729 1,093,619  
Selling, general and administrative 1,500,324 820,203 2,963,858  
Total operating expenses 75,196 2,006,694 1,178,932 4,057,477  
Income (loss) from discontinued operations (89,749) 1,660,693 1,359,536 2,850,540  
Interest expense (7,525,483) (1,718,506) (9,719,763)  
Loss before income taxes (89,749) (5,864,790) (358,970) (6,869,223)  
Benefit from income taxes 7,373 20,733  
Loss from discontinued operations $ (82,376) $ (5,864,790) $ (338,237) $ (6,869,223)